Latest Cumberland Pharmaceuticals Inc. Stories
NASHVILLE, Tenn., May 15, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the UBS Global Healthcare Conference at the Sheraton New York hotel on Monday, May 20, 2013, at 9:30 a.m. Eastern Time. The presentation will be simultaneously webcast and can be accessed through the Investor Relations section of...
- Diluted earnings per share increased 150% to $0.05 NASHVILLE, Tenn., May 2, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2013 financial results. Net Revenue: For the three months ended March 31, 2013, net revenue was $10.3 million, in line with net revenues from the first quarter of 2012. Operating Expenses: Total operating expenses for...
NASHVILLE, Tenn., April 25, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release its first quarter 2013 results after the market closes on Thursday, May 2, 2013. A conference call and live Internet webcast will be held on Thursday, May 2, 2013, at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the...
- Net income increased nearly 100% in fourth quarter. NASHVILLE, Tenn., Feb. 28, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2012 financial results. Net Revenue: For the three months ended December 31, 2012, net revenue was $13.7 million, up from $13.0 million in the prior year period. For the year ended December 31, 2012,...
NASHVILLE, Tenn., Feb. 19, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced top-line results from two registry studies evaluating the safety and efficacy of Caldolor® (ibuprofen) Injection administered over a shortened infusion time in treating pain and fever in adult patients. The studies involved 450 patients receiving Caldolor at 35 leading medical centers throughout the United States. The first of two registry studies was a phase IV...
NASHVILLE, Tenn., Feb. 14, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release 2012 year-end financial results after the market closes on Thursday, February 28, 2013. A conference call and live Internet webcast will be held on Thursday, February 28, 2013, at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A...
NASHVILLE, Tenn., Jan. 29, 2013 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) today announced it has entered into an exclusive agreement with Indonesia's PT. SOHO Industri Pharmasi (a SOHO Group company) for the registration and commercialization of Caldolor® (ibuprofen) Injection, which is used to treat pain and fever in the hospital setting. Under the terms of the agreement, SOHO receives an exclusive license to Caldolor for the Indonesian market. SOHO will be...
NASHVILLE, Tenn., Nov. 7, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc.(NASDAQ: CPIX) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for a second patent relating to its new formulation of Acetadote(® )(acetylcysteine) Injection, which is used to treat acetaminophen overdose. The original composition of matter patent covered the Acetadote formulation and was issued in April 2012. The new patent includes claims...
NASHVILLE, Tenn., Oct. 18, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release third quarter 2012 results after the market closes on Thursday, November 1, 2012. A conference call and live Internet webcast will be held on Thursday, November 1, at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the...
NASHVILLE, Tenn., Oct. 11, 2012 /PRNewswire/ -- Cumberland Emerging Technologies, Inc. (CET) today announced that three tenants at its Nashville Life Sciences Center have been awarded $3.2 million in federal small business grants. The grantees, which include Jericho Sciences LLC, and a research alliance comprised of Cumberland Pharmaceuticals Inc., CET, and the University of Virginia, will use the funding to support their work in developing new medical therapies. Jericho Sciences LLC...
